trastuzumab,rucaparib,anbalcabtagene,alectinib,tucatinib,trastuzumab deruxtecan,vismodegib,atezolizumab,vemurafenib,pertuzumab,cobimetinib
daiichi sankyo,roche,curocell,seagen,clovis oncology,astrazeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crc-01', 'mountaineer', 'destiny,crc,01', 'destiny,crc,02', 'mypathway', 'triumph']
great overview on targeting her2 in mcrc by prof.salvatore siena #wcgic2023 
Oncologist, M.D. IEO, Division of Gastrointestinal and Neuroendocrine Tumors.